TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21342747

Group type: EXPERIMENTAL
Intervention: Active rTMS followed by sham rTMS
Number of subjects: 45

Group type: COMPARATOR
Intervention: Sham rTMS before any active rTMS
Number of subjects: 45
Study: 20530934

Group type: EXPERIMENTAL
Intervention: L-carnitine supplementation (2 g/day)
Number of subjects: 0
Study: 17373090

Group type: EXPERIMENTAL
Intervention: Terbinafine 250 mg/day + aggressive debridement
Number of subjects: 504

Group type: COMPARATOR
Intervention: Terbinafine 250 mg/day alone
Number of subjects: 504
Study: 15111485

Group type: EXPERIMENTAL
Intervention: Liraglutide (6 micro g/kg) administered subcutaneously once daily
Number of subjects: 13
Study: 11813932

Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2% twice daily
Number of subjects: 127

Group type: COMPARATOR
Intervention: Latanoprost 0.005% once daily
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2% twice daily (treatment-naive)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Latanoprost 0.005% once daily (treatment-naive)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2% twice daily (previously treated)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Latanoprost 0.005% once daily (previously treated)
Number of subjects: 127
Study: 11502237

Group type: EXPERIMENTAL
Intervention: Yoghurt-based drink enriched with 1 g plant sterol extracted from soyabean/d
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Yoghurt-based drink enriched with 2 g plant sterols/d
Number of subjects: 30

Group type: COMPARATOR
Intervention: Low-fat low-lactose yoghurt
Number of subjects: 30
Study: 9041099

Group type: EXPERIMENTAL
Intervention: Ursodiol (13 to 15 mg per kilogram of body weight per day in divided doses)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Ursodiol
Number of subjects: 105
Study: 8282745

Group type: EXPERIMENTAL
Intervention: Limited anterior plication (LAP)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Superficial veins surgery (Group 1)
Number of subjects: 11
Study: 3434884

Group type: EXPERIMENTAL
Intervention: Ketoprofen
Number of subjects: 59

Group type: COMPARATOR
Intervention: Pethidine
Number of subjects: 59
Study: 1978115

Group type: EXPERIMENTAL
Intervention: L1 (50 mg/kg daily by mouth)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Desferrioxamine (50 mg/kg daily as a 12 h subcutaneous infusion)
Number of subjects: 26
Study: 31213144

Group type: EXPERIMENTAL
Intervention: Suicidal patient condition
Number of subjects: 249

Group type: COMPARATOR
Intervention: Depressive patient condition
Number of subjects: 249
Study: 29938533

Group type: EXPERIMENTAL
Intervention: Ranolazine (6-week add-on therapy)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard treatment without additional study medication (Control)
Number of subjects: 20
Study: 28658582

Group type: EXPERIMENTAL
Intervention: Acute nitrate supplementation (10 mg·kg‐1 body mass of sodium nitrate)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo (sodium chloride)
Number of subjects: 11
Study: 25580630

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 83
Study: 23666445

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of ascorbic acid (7.5 g)
Number of subjects: 89
Study: 22524083

Group type: EXPERIMENTAL
Intervention: Midazolam 0.5mg/kg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Triclofos 70mg/kg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (no medication)
Number of subjects: 12
Study: 19017773

Group type: EXPERIMENTAL
Intervention: Web-based care management for 12 months
Number of subjects: 83

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 83
Study: 17374416

Group type: EXPERIMENTAL
Intervention: Sildenafil citrate 50 mg daily for 30 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 15504376

Group type: EXPERIMENTAL
Intervention: Implanon
Number of subjects: 80

Group type: COMPARATOR
Intervention: Norplant
Number of subjects: 80
Study: 11782329

Group type: COMPARATOR
Intervention: IT fentanyl 25 microg plus normal saline (Group f)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: IT fentanyl 25 microg plus plain bupivacaine 1.25 mg (Group f+pb)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: IT fentanyl 25 microg plus heavy bupivacaine 1.25 mg (Group f+hb)
Number of subjects: 48
Study: 9824781

Group type: EXPERIMENTAL
Intervention: 20 mg intravenously
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 40 mg orally
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 20 mg intravenously or 40 mg orally every 12 hours
Number of subjects: 13
Study: 8861410

Group type: EXPERIMENTAL
Intervention: Behavioural treatment including applied relaxation, video self‐modelling, exposure, information, and teaching of hearing tactics
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Behavioural treatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 20
Study: 2667324

Group type: EXPERIMENTAL
Intervention: epirubicin 90 mg/m2 (75 mg/m2 if prior radiotherapy) i.v. once every 3 weeks
Number of subjects: 77

Group type: COMPARATOR
Intervention: 5-fluorouracil 500 mg/m2 (450 mg/m2 if prior radiotherapy) i.v. once daily for 5 consecutive days every 4 weeks
Number of subjects: 77
Study: 1106936

Group type: EXPERIMENTAL
Intervention: 220 mg of naproxen
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: 330 mg of naproxen
Number of subjects: 197
Study: 30559067

Group type: COMPARATOR
Intervention: Patient-controlled analgesia (systemically administered opioids)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Paravertebral analgesia (perioperative continuous thoracic paravertebral block with local anesthetic)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Paravertebral analgesia
Number of subjects: 44

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 44
Study: 27995547

Group type: EXPERIMENTAL
Intervention: Deceptive placebo manipulation
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Non-deceptive placebo manipulation
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: All groups (deceptive, non-deceptive, control)
Number of subjects: 75
Study: 25271378

Group type: EXPERIMENTAL
Intervention: Insulin degludec (IDeg)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Insulin glargine (IGlar)
Number of subjects: 2
Study: 23647445

Group type: EXPERIMENTAL
Intervention: Fingolimod 0.5 mg once daily for 6 months
Number of subjects: 1053

Group type: COMPARATOR
Intervention: Standard-of-care DMTs
Number of subjects: 1053
Study: 21596735

Group type: EXPERIMENTAL
Intervention: L-arginine plus antioxidant vitamins
Number of subjects: 222

Group type: COMPARATOR
Intervention: Antioxidant vitamins alone
Number of subjects: 222
Study: 19806851

Group type: EXPERIMENTAL
Intervention: Culturally specific booklet
Number of subjects: 261

Group type: COMPARATOR
Intervention: Standard booklet
Number of subjects: 261
Study: 17935674

Group type: EXPERIMENTAL
Intervention: Insulin Aspart
Number of subjects: 21
Study: 15472572

Group type: EXPERIMENTAL
Intervention: Diazepam (5 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 11427637

Group type: EXPERIMENTAL
Intervention: Methylene blue (MB) given as a bolus of 1 mg/kg bodyweight followed by a constant infusion of 0.1 mg/kg bodyweight for 210 min during dialysis
Number of subjects: 41

Group type: COMPARATOR
Intervention: Healthy controls (no intervention)
Number of subjects: 41
Study: 9531074

Group type: EXPERIMENTAL
Intervention: Meropenem (0.5 g 8-hourly)
Number of subjects: 393

Group type: COMPARATOR
Intervention: Ceftazidime (1 g 8-hourly)
Number of subjects: 393
Study: 8028055

Group type: EXPERIMENTAL
Intervention: Parenteral nutrition (TPN)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Enteral nutrition (TEN)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Parenteral plus enteral nutrition (PN/EN)
Number of subjects: 37

Group type: COMPARATOR
Intervention: All groups (TPN, TEN, PN/EN)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: TEN and PN/EN
Number of subjects: 37

Group type: COMPARATOR
Intervention: Complications (gastric reflux or abdominal distention)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Complications (ARDS and respiratory infection)
Number of subjects: 37
Study: 2567715

Group type: EXPERIMENTAL
Intervention: Intrauterine insemination (IUI)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Whole‐ejaculate intracervical insemination (ICI)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Intercourse after missing inseminations
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Intrauterine insemination (IUI) for male factor (MF) patients
Number of subjects: 73
Study: 30911756

Group type: COMPARATOR
Intervention: 2× daily feeding (half ration at 0730 and 1530 h)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: 3× daily feeding (a third portion at 0730, 1130, and 1530 h)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: 2× daily feeding
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: 3× daily feeding
Number of subjects: 177
Study: 28760664

Group type: EXPERIMENTAL
Intervention: 10ppm OHA
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: 20ppm OHA
Number of subjects: 4

Group type: COMPARATOR
Intervention: Control (no OHA)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: R (water from 20 OHA group, no OHA)
Number of subjects: 4
Study: 26603186

Group type: EXPERIMENTAL
Intervention: Palliative Advanced Home Care and Heart Failure Care intervention
Number of subjects: 72

Group type: COMPARATOR
Intervention: Usual care provided by a primary health care center or heart failure clinic
Number of subjects: 72
Study: 24178238

Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patch (2 mg/24 h) applied for 24 h
Number of subjects: 48
Study: 22103674

Group type: EXPERIMENTAL
Intervention: Adapalene 0.1% and benzoyl peroxide 2.5% (A-BPO)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 0
Study: 20031846

Group type: EXPERIMENTAL
Intervention: Uncertainty reduction intervention (provided in 5 clinics) including access to a specially designed study form with blood pressure graphs, assessment checkboxes, and a menu of services (24-hour ambulatory blood pressure monitoring, electronic bottle cap assessment of medication adherence, lifestyle assessment and counseling).
Number of subjects: 680

Group type: COMPARATOR
Intervention: Usual care (provided in 5 clinics) without access to the intervention services.
Number of subjects: 680

Group type: EXPERIMENTAL
Intervention: Uncertainty reduction intervention
Number of subjects: 680

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 680
Study: 17802891

Group type: EXPERIMENTAL
Intervention: Composite Denshen Pilulae, 10# tid for 2 weeks
Number of subjects: 24
Study: 14977388

Group type: EXPERIMENTAL
Intervention: Ciclesonide 80 microg once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ciclesonide 320 microg once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ciclesonide 320 microg daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Budesonide 400 microg daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ciclesonide 80 or 320 microg daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ciclesonide
Number of subjects: 0
Study: 11194406

Group type: EXPERIMENTAL
Intervention: Tartar-control mouthrinse containing zinc chloride
Number of subjects: 334

Group type: COMPARATOR
Intervention: Tartar-control dentifrice containing pyrophosphate (positive control)
Number of subjects: 334

Group type: COMPARATOR
Intervention: Regular dentifrice and antiseptic rinse (negative control)
Number of subjects: 334
Study: 9741504

Group type: EXPERIMENTAL
Intervention: Any atenolol
Number of subjects: 40844

Group type: EXPERIMENTAL
Intervention: Intravenous and oral atenolol
Number of subjects: 40844

Group type: EXPERIMENTAL
Intervention: Intravenous atenolol
Number of subjects: 40844

Group type: EXPERIMENTAL
Intervention: Oral atenolol
Number of subjects: 40844

Group type: COMPARATOR
Intervention: No atenolol
Number of subjects: 40844
Study: 7991337

Group type: EXPERIMENTAL
Intervention: Reconstruction of experiences in the same context
Number of subjects: 20

Group type: COMPARATOR
Intervention: Reconstruction of experiences outside of the context
Number of subjects: 20
Study: 2543999

Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 31577520

Group type: EXPERIMENTAL
Intervention: Leucine supplementation (5g) with resistance training (RT)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo supplementation with resistance training (RT)
Number of subjects: 36
Study: 30552406

Group type: EXPERIMENTAL
Intervention: Low-dose rosuvastatin
Number of subjects: 732

Group type: COMPARATOR
Intervention: Telmisartan
Number of subjects: 732

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 732

Group type: EXPERIMENTAL
Intervention: Telmisartan + Low-dose rosuvastatin
Number of subjects: 732

Group type: COMPARATOR
Intervention: Placebo + Low-dose rosuvastatin
Number of subjects: 732
Study: 28322748

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (OT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24585100

Group type: EXPERIMENTAL
Intervention: HDM allergen extract for SLIT
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 23801303

Group type: EXPERIMENTAL
Intervention: Cediranib 45 mg/day plus fulvestrant
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo plus fulvestrant
Number of subjects: 62
Study: 20683084

Group type: EXPERIMENTAL
Intervention: Home-based walking intervention
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Enhanced treatment
Number of subjects: 148

Group type: COMPARATOR
Intervention: Objective crime measures
Number of subjects: 148
Study: 19038708

Group type: EXPERIMENTAL
Intervention: Platelet concentrate (PC)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Bone plug (BP)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Combination of PC and BP
Number of subjects: 108
Study: 15923042

Group type: EXPERIMENTAL
Intervention: Fluoxetine monotherapy 10-30 mg daily
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Olanzapine monotherapy 5-20 mg daily
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Combined fluoxetine plus olanzapine therapy 10-40 mg plus 5-15 mg daily
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 12822744

Group type: EXPERIMENTAL
Intervention: Fenofibrate (n = 26)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo (n = 27)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Overall (both groups)
Number of subjects: 53
Study: 10693711

Group type: EXPERIMENTAL
Intervention: CO2 and nonionic contrast material
Number of subjects: 40

Group type: COMPARATOR
Intervention: CO2 alone
Number of subjects: 40

Group type: COMPARATOR
Intervention: CO2 and gadodiamide
Number of subjects: 40

Group type: COMPARATOR
Intervention: CO2 and nonionic contrast material vs CO2 alone and gadodiamide
Number of subjects: 40

Group type: COMPARATOR
Intervention: CO2 and nonionic contrast material vs CO2 and gadodiamide
Number of subjects: 40
Study: 8794412

Group type: EXPERIMENTAL
Intervention: Chemo-immunotherapy (IL-2 and LAK cells after two courses of anticancer chemotherapy)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control (no adjuvant therapy)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Chemotherapy (same anticancer chemotherapy as group A)
Number of subjects: 82
Study: 8392151

Group type: EXPERIMENTAL
Intervention: Migraine without aura (MO)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Migraine with aura (MA)
Number of subjects: 193

Group type: COMPARATOR
Intervention: General population
Number of subjects: 193
Study: 3522507

Group type: EXPERIMENTAL
Intervention: Piracetam (3.3 g/day in two divided doses for 12 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (matching placebo for 12 weeks)
Number of subjects: 0
Study: 31232197

Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 5
Study: 29341461

Group type: COMPARATOR
Intervention: Exenatide infusion (Study-A)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Exenatide infusion (Study-B)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Liraglutide (Study-C)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Lixisenatide (Study-D)
Number of subjects: 132
Study: 24380501

Group type: EXPERIMENTAL
Intervention: Multi-component educational intervention (small media, academic detailing, and website for providers; printed educational materials for patients)
Number of subjects: 2246

Group type: COMPARATOR
Intervention: Printed copies of general guidelines
Number of subjects: 2246
Study: 22622291

Group type: EXPERIMENTAL
Intervention: Ketamine (0.8 mg/kg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Propofol plus Ketamine (1.5 mg/kg + 0.8 mg/kg)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Propofol (1.5 mg/kg)
Number of subjects: 48
Study: 20394542

Group type: EXPERIMENTAL
Intervention: Topical anti-glaucoma medications (AGM)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (no topical medications)
Number of subjects: 96
Study: 18588760

Group type: EXPERIMENTAL
Intervention: Vardenafil
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Local decongestant
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Vardenafil + Local decongestant
Number of subjects: 14
Study: 15965687

Group type: EXPERIMENTAL
Intervention: Whole-body (18)F‐FDG PET after one or two courses of induction chemotherapy (IC)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Major responders (downstaged to stage I or II)
Number of subjects: 50
Study: 12069285

Group type: EXPERIMENTAL
Intervention: Traditional Chinese acupuncture (TCA)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ear acupuncture (EA)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Korean hand acupuncture (KHA)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo needling (PN)
Number of subjects: 20
Study: 10520784

Group type: EXPERIMENTAL
Intervention: Abrupt cessation of intravenous unfractionated heparin (UFH)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Intravenous weaning over 12 hours
Number of subjects: 30

Group type: COMPARATOR
Intervention: Subcutaneous weaning over 12 hours
Number of subjects: 30
Study: 7830033

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 10

Group type: COMPARATOR
Intervention: Enalapril and Doxazosin
Number of subjects: 10
Study: 2115686

Group type: EXPERIMENTAL
Intervention: Insulin Novo Protaphan HM Penfill (100 IU/ml 'bed time') and 10 mg of glibenclamide in the morning (group A)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Insulin Novo Actraphan HM Penfill (100 IU/ml in the morning) combined with two 5 mg doses of glibenclamide at lunchtime and in the evening (group B)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Glibenclamide dropout period
Number of subjects: 28
Study: 844351

Group type: EXPERIMENTAL
Intervention: 3 checkerboards
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 4 checkerboards
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5 checkerboards
Number of subjects: 0
Study: 31915696

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 32
Study: 29735813

Group type: EXPERIMENTAL
Intervention: L-tyrosine (100 mg/kg/day)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 26048342

Group type: EXPERIMENTAL
Intervention: Schisandra chinensis fruit (SCF)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 23926751

Group type: EXPERIMENTAL
Intervention: Nurse telephone coaching intervention
Number of subjects: 0
Study: 21798407

Group type: EXPERIMENTAL
Intervention: 0.02% mitomycin C (MMC) applied intra-operatively for 30 seconds over the ablated zone
Number of subjects: 64

Group type: COMPARATOR
Intervention: No mitomycin C (MMC)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Comparison of CCT changes between groups 1 and 2
Number of subjects: 64
Study: 19564995

Group type: EXPERIMENTAL
Intervention: TIMER (Tool to Improve Medications in the Elderly via Review)
Number of subjects: 244
Study: 16229010

Group type: EXPERIMENTAL
Intervention: Rivastigmine 3-12 mg/day
Number of subjects: 433

Group type: COMPARATOR
Intervention: Rivastigmine (for placebo patients switching)
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: Rivastigmine
Number of subjects: 433
Study: 15327641

Group type: EXPERIMENTAL
Intervention: Rinsing with mouthrinses formulated with chlorhexidine, cetylpyridinium chloride or triclosan/copolymer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brushing with a triclosan/copolymer dentifrice
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rinsing with a sucrose solution
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rinsing with water, a commercially available fluoride mouthrinse without antimicrobial agents, or brushing with a fluoride dentifrice
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chlorhexidine rinses
Number of subjects: 0
Study: 11194173

Group type: EXPERIMENTAL
Intervention: Soft gelatin capsules containing 300 mg of alcoholic Hypericum extract (5% hyperforin and 0.3% hypericin)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Hard gelatin capsules (standard formulation)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Soft gelatin capsules
Number of subjects: 12
Study: 9313185

Group type: EXPERIMENTAL
Intervention: Semi-Fowler's position with left lateral tilt
Number of subjects: 573

Group type: EXPERIMENTAL
Intervention: Semi-Fowler's position with right lateral tilt
Number of subjects: 573

Group type: COMPARATOR
Intervention: Semi-Fowler's position without lateral tilt (Control)
Number of subjects: 573
Study: 8489054

Group type: EXPERIMENTAL
Intervention: Phenylephrine (1 micrograms/kg)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Norepinephrine (0.05 micrograms/kg)
Number of subjects: 38
Study: 2442553

Group type: EXPERIMENTAL
Intervention: Lisinopril 40-80 mg/day
Number of subjects: 115

Group type: COMPARATOR
Intervention: Metoprolol 100-200 mg/day
Number of subjects: 115